Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.68

-2.4%

Dec 12 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ploni	9/22/2006 1:56:35 PM
	Read Replies (1) of 52153

Can anyone translate this for me, from today's PARD press release: "A total of 77 patients were treated with picoplatin in the [Phase II] trial, which is designed to confirm the clinical activity of picoplatin as second-line therapy in patients with platinum-resistant or -refractory SCLC [small cell lung cancer] who have failed a prior platinum-based chemotherapy. Preliminary results from the 54 patients evaluable for response indicate that approximately 50 percent of the patients have shown evidence of stable disease. Clinical data from this ongoing trial, including preliminary median overall survival data, are expected to be available in the fourth quarter of this year." First, what does it mean that only 54 out of 77 patients were evaluable for response? Did the others die? What does it mean that 50% of patients show stable disease? That they aren't getting worse? Is that good? Don't we want them to get better? What is the significance of this press release, other than to say that they are in a trial?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next